101 related articles for article (PubMed ID: 17107924)
21. Imatinib trough levels in chronic myelogenous leukemia: does one dose fit all?
Yeung DT; White DL
Leuk Lymphoma; 2011 Feb; 52(2):165-7. PubMed ID: 21171867
[No Abstract] [Full Text] [Related]
22. Imatinib mesylate induced immune thrombocytopenia.
Rajappa S; Varadpande L; Paul TR; Digumarti R
Leuk Lymphoma; 2007 Nov; 48(11):2261-3. PubMed ID: 17926182
[No Abstract] [Full Text] [Related]
23. The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia.
Quintás-Cardama A; Kantarjian H; Cortes J
Leuk Lymphoma; 2007 Apr; 48(4):802-4. PubMed ID: 17454640
[No Abstract] [Full Text] [Related]
24. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
25. [Disease transformation in imatinib mesylate treated Philadelphia chromosome-positive chronic myelogenous leukemia patients achieved cytogenetic remissions].
Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Lu DP
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 37(6):612-5. PubMed ID: 16378113
[TBL] [Abstract][Full Text] [Related]
26. Which TKI should be recommended as initial treatment for CML in chronic phase?
Schiffer CA
Oncology (Williston Park); 2012 Oct; 26(10):912, 914. PubMed ID: 23175997
[No Abstract] [Full Text] [Related]
27. New agent overcomes resistance to imatinib.
Ahmad K
Lancet Oncol; 2005 Mar; 6(3):137. PubMed ID: 15759363
[No Abstract] [Full Text] [Related]
28. Successful outcome of pregnancy in a patient with chronic myelogenous leukemia exposed to imatinib during the first trimester.
Suppiah R; Kalaycio M
Leuk Lymphoma; 2006 Jun; 47(6):1149-50. PubMed ID: 16840209
[No Abstract] [Full Text] [Related]
29. Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia.
Kong JH; Yoo SH; Lee KE; Nam SH; Kwon JM; Lee SM; Chang HJ; Choi MY; Cho MS; Mun YC; Nam E; Lee SN; Seong CM
Acta Haematol; 2007; 118(4):205-8. PubMed ID: 18030002
[TBL] [Abstract][Full Text] [Related]
30. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
31. Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia.
Barton JC; Jones SC; Lamberth WC; Reymann MT; Scott VC
Am J Hematol; 2002 Oct; 71(2):139-40. PubMed ID: 12353320
[No Abstract] [Full Text] [Related]
32. Front-line TKI therapy for chronic-phase CML: the luxury of choice.
Shah NP
Oncology (Williston Park); 2012 Oct; 26(10):908, 910, 912. PubMed ID: 23175996
[No Abstract] [Full Text] [Related]
33. [Analysis of efficacy and related factors in 85 chronic myeloid leukemia patients treated with imatinib mesylate].
Zhou KS; Wang YY; Zhao YZ; Yi SH; Qian LS; Wang GR; Yu Z; Wang Y; Wang JX; Qiu LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):208-12. PubMed ID: 20137149
[TBL] [Abstract][Full Text] [Related]
34. Imatinib for chronic myeloid leukaemia: a NICE mess.
Rajaratnam G; Edwards J
Lancet; 2001 Dec; 358(9296):1902. PubMed ID: 11741655
[No Abstract] [Full Text] [Related]
35. Presence of complex t(6;9;22;15) four-way chromosome rearrangement plus rare t(1;6) translocation with favorable response to imatinib therapy in chronic myelogenous leukemia.
Lu CM; Zhou L; Feng S; Kohn PH; Qi Z; Yu J
Leuk Lymphoma; 2011 Nov; 52(11):2182-4. PubMed ID: 21718138
[No Abstract] [Full Text] [Related]
36. Endogenous erythroid colony formation in chronic myeloid leukemia: a recurrent finding associated with persistent minimal residual disease under imatinib.
Einwallner E; Jaeger E; Mitterbauer-Hohendanner G; Bilban M; Simonitsch-Klupp I; Steiner I; Pernicka E; Hoermann G; Herndlhofer S; Sillaber C; Valent P; Schwarzinger I
Stem Cells Dev; 2013 Dec; 22(23):3043-51. PubMed ID: 23883175
[TBL] [Abstract][Full Text] [Related]
37. The effect of homoharringtonine in patients with chronic myeloid leukemia who have failed or responded suboptimally to imatinib therapy.
Li YF; Liu X; Liu DS; Din BH; Zhu JB
Leuk Lymphoma; 2009 Nov; 50(11):1889-91. PubMed ID: 19860613
[No Abstract] [Full Text] [Related]
38. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
[TBL] [Abstract][Full Text] [Related]
39. Roth spots in chronic myelogenous leukemia.
Kapadia RK; Steeves JH
CMAJ; 2011 Dec; 183(18):E1352. PubMed ID: 21930739
[No Abstract] [Full Text] [Related]
40. Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.
Murphy M; Close J; Lottenberg R; Rajasekhar A
Am J Med Sci; 2014 Mar; 347(3):254-5. PubMed ID: 24553361
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
